News

Small Caps – Proteomics commences European campaign to advance PromarkerD diabetic kidney disease test

The Spanish launch marks the first European country where the test will be available and sets the stage for broader geographic distribution in the coming months.

The move was dubbed as a “pivotal milestone” by the medical technology company as it attempts to broaden awareness of the test and establish additional licensing transactions and jurisdictional launches.

Some potential markets already mentioned by Proteomics include 26 other European nations, Japan, India and the United States.

News of the Spanish launch boosted Proteomics shares by almost 12%, up to $0.335 per share this morning.

Article: Proteomics commences European campaign to advance PromarkerD diabetic kidney disease test

ASX Release

Subscribe
  • This field is for validation purposes and should be left unchanged.